German scientist Paul Ehrlich introduced a groundbreaking concept to the world: chemical compounds could be engineered to ...

Explore BIG's innovative museum design in Debrecen, featuring a mass timber structure and immersive educational experiences.

Daiichi Sankyo (DSNKY) and AstraZeneca’s Enhertu has been approved in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic hor ...

By then, AstraZeneca and cancer drug partner Daiichi Sankyo had already validated the blockbuster potential of HER2-directed ADCs with Enhertu. But Eisai identified BB-1701 as a potential best-in ...

AstraZeneca (AZ) and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved by the European Commission (EC) to treat a broader population of HER2-low breast cancer patients. The drug has ...

A University of Iowa-led study has revealed the unexpected structure adopted by the DNA repair protein RAD52 as it binds and protects replicating DNA in dividing cells. This new structural and ...

AstraZeneca PLC (LSE:LON:AZN), a pharmaceutical giant with a market capitalization of $224 billion and an impressive gross profit margin of 82%, announced today that its drug Enhertu has been ...

AstraZeneca PLC (LSE:LON:AZN), a pharmaceutical giant with a market capitalization of $224 billion and an impressive gross profit margin of 82%, announced today that its drug Enhertu has been approved ...

The Cambridge, England-based pharmaceuticals firm said Enhertu, or trastuzumab deruxtecan, has been approved in the EU as a therapy for adult patients with unresectable or metastatic hormone ...

(RTTNews) - AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) Enhertu (trastuzumab deruxtecan) has been approved in the European Union as a treatment for adults with advanced breast ...

Structural safety is critical to preventing failures that can lead to catastrophic consequences, including economic losses and threats to human life.